In Q2 of fiscal 2027, the quarter ended Jul 31, 2026, Vitaspring Biomedical Co., Ltd. generated $5,200 of cash from operations, up 538.4% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jul 31, 2026
|
Q2 FY2027
Jul 31, 2026
|
Q1 FY2027
Apr 30, 2026
|
Q4 FY2026
Jan 31, 2026
|
Q3 FY2026
Oct 31, 2025
|
Q2 FY2026
Jul 31, 2025
|
Q1 FY2026
Apr 30, 2025
|
Q4 FY2025
Jan 31, 2025
|
Q3 FY2025
Oct 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
—
|
0
|
—
|
0
|
0
+200.0%
|
—
|
0
+0.0%
|
—
|
0
-33.9%
|
| Stock-based compensation |
—
|
—
|
—
|
0
|
0
-100.0%
|
0
-100.0%
|
0
-100.0%
|
0
-100.0%
|
0
-33.3%
|
| Operating cash flow |
0
+203.6%
|
0
+538.4%
|
0
+872.9%
|
0
+106.9%
|
-0
+87.0%
|
-0
+51.0%
|
-0
+80.4%
|
-0
+31.8%
|
-0
-41.7%
|
| Financing | |||||||||
| Financing cash flow |
0
-63.5%
|
0
-100.0%
|
0
-100.0%
|
0
|
0
-32.8%
|
0
-71.6%
|
0
-89.7%
|
0
|
0
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- VSBC (OTC)
- Fiscal year ends
- January 31
- Incorporated in
- NV
- Headquarters
- Riverside, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1697884
- Former names
- Shemn Corp. (until Apr 27, 2020)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.